IBDEI1EP ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22748,2)
 ;;=^5001059
 ;;^UTILITY(U,$J,358.3,22749,0)
 ;;=C44.622^^76^978^15
 ;;^UTILITY(U,$J,358.3,22749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22749,1,3,0)
 ;;=3^SCC Skin Right Upper Limb
 ;;^UTILITY(U,$J,358.3,22749,1,4,0)
 ;;=4^C44.622
 ;;^UTILITY(U,$J,358.3,22749,2)
 ;;=^5001070
 ;;^UTILITY(U,$J,358.3,22750,0)
 ;;=C44.629^^76^978^6
 ;;^UTILITY(U,$J,358.3,22750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22750,1,3,0)
 ;;=3^SCC Skin Left Upper Limb
 ;;^UTILITY(U,$J,358.3,22750,1,4,0)
 ;;=4^C44.629
 ;;^UTILITY(U,$J,358.3,22750,2)
 ;;=^5001071
 ;;^UTILITY(U,$J,358.3,22751,0)
 ;;=C44.722^^76^978^14
 ;;^UTILITY(U,$J,358.3,22751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22751,1,3,0)
 ;;=3^SCC Skin Right Lower Limb
 ;;^UTILITY(U,$J,358.3,22751,1,4,0)
 ;;=4^C44.722
 ;;^UTILITY(U,$J,358.3,22751,2)
 ;;=^5001082
 ;;^UTILITY(U,$J,358.3,22752,0)
 ;;=C44.729^^76^978^5
 ;;^UTILITY(U,$J,358.3,22752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22752,1,3,0)
 ;;=3^SCC Skin Left Lower Limb
 ;;^UTILITY(U,$J,358.3,22752,1,4,0)
 ;;=4^C44.729
 ;;^UTILITY(U,$J,358.3,22752,2)
 ;;=^5001083
 ;;^UTILITY(U,$J,358.3,22753,0)
 ;;=C44.82^^76^978^10
 ;;^UTILITY(U,$J,358.3,22753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22753,1,3,0)
 ;;=3^SCC Skin Overlapping Sites
 ;;^UTILITY(U,$J,358.3,22753,1,4,0)
 ;;=4^C44.82
 ;;^UTILITY(U,$J,358.3,22753,2)
 ;;=^5001089
 ;;^UTILITY(U,$J,358.3,22754,0)
 ;;=L57.8^^76^978^36
 ;;^UTILITY(U,$J,358.3,22754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22754,1,3,0)
 ;;=3^Skin Changes d/t Chr Exposure to Nonionizing Radiation
 ;;^UTILITY(U,$J,358.3,22754,1,4,0)
 ;;=4^L57.8
 ;;^UTILITY(U,$J,358.3,22754,2)
 ;;=^5009226
 ;;^UTILITY(U,$J,358.3,22755,0)
 ;;=L27.0^^76^978^37
 ;;^UTILITY(U,$J,358.3,22755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22755,1,3,0)
 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,22755,1,4,0)
 ;;=4^L27.0
 ;;^UTILITY(U,$J,358.3,22755,2)
 ;;=^5009144
 ;;^UTILITY(U,$J,358.3,22756,0)
 ;;=L27.1^^76^978^38
 ;;^UTILITY(U,$J,358.3,22756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22756,1,3,0)
 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,22756,1,4,0)
 ;;=4^L27.1
 ;;^UTILITY(U,$J,358.3,22756,2)
 ;;=^5009145
 ;;^UTILITY(U,$J,358.3,22757,0)
 ;;=L51.1^^76^978^44
 ;;^UTILITY(U,$J,358.3,22757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22757,1,3,0)
 ;;=3^Stevens-Johnson Syndrome
 ;;^UTILITY(U,$J,358.3,22757,1,4,0)
 ;;=4^L51.1
 ;;^UTILITY(U,$J,358.3,22757,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,22758,0)
 ;;=L51.3^^76^978^45
 ;;^UTILITY(U,$J,358.3,22758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22758,1,3,0)
 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
 ;;^UTILITY(U,$J,358.3,22758,1,4,0)
 ;;=4^L51.3
 ;;^UTILITY(U,$J,358.3,22758,2)
 ;;=^336637
 ;;^UTILITY(U,$J,358.3,22759,0)
 ;;=Z12.83^^76^978^21
 ;;^UTILITY(U,$J,358.3,22759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22759,1,3,0)
 ;;=3^Screening for Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,22759,1,4,0)
 ;;=4^Z12.83
 ;;^UTILITY(U,$J,358.3,22759,2)
 ;;=^5062696
 ;;^UTILITY(U,$J,358.3,22760,0)
 ;;=Z48.817^^76^978^48
 ;;^UTILITY(U,$J,358.3,22760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22760,1,3,0)
 ;;=3^Surgical Aftercare Following Skin Surgery
 ;;^UTILITY(U,$J,358.3,22760,1,4,0)
 ;;=4^Z48.817
 ;;^UTILITY(U,$J,358.3,22760,2)
 ;;=^5063054
